Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 350

1.

Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10+ diffuse large B-cell lymphoma and follicular lymphoma.

Azoulay D, Cohen HI, Dementiev E, Eshel E, Akria L, Shaoul E, Horowitz N.

Cytometry B Clin Cytom. 2019 Dec 9. doi: 10.1002/cyto.b.21861. [Epub ahead of print]

PMID:
31816181
2.

Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation.

Horowitz NS, Berkowitz RS, Elias KM.

Obstet Gynecol. 2019 Dec 5. doi: 10.1097/AOG.0000000000003625. [Epub ahead of print] No abstract available.

PMID:
31809444
3.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

4.

Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer.

Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN.

Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32783. [Epub ahead of print]

PMID:
31714586
5.

State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia.

Elias KM, Berkowitz RS, Horowitz NS.

J Natl Compr Canc Netw. 2019 Nov 1;17(11):1396-1401. doi: 10.6004/jnccn.2019.7364.

PMID:
31693988
6.

Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.

Shimony S, Horowitz N, Ribakovsky E, Rozovski U, Avigdor A, Zloto K, Berger T, Avivi I, Perry C, Abadi U, Raanani P, Gafter-Gvili A, Gurion R.

Hematol Oncol. 2019 Oct 31. doi: 10.1002/hon.2691. [Epub ahead of print]

PMID:
31674027
7.

Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough?

Elias KM, Berkowitz RS, Horowitz NS.

Gynecol Oncol. 2019 Oct;155(1):1-2. doi: 10.1016/j.ygyno.2019.09.006. No abstract available.

PMID:
31601360
8.

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS.

JAMA Oncol. 2019 Oct 10. doi: 10.1001/jamaoncol.2019.3343. [Epub ahead of print]

PMID:
31600397
9.
10.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
11.

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF.

Gynecol Oncol Rep. 2019 Aug 10;29:118-122. doi: 10.1016/j.gore.2019.07.010. eCollection 2019 Aug.

12.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I.

Immunity. 2019 Aug 20;51(2):411-412. doi: 10.1016/j.immuni.2019.08.004. No abstract available.

13.

Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.

Perry C, Ben Barouch S, Goldschmidt N, Sarid N, Herishanu Y, Shvidel L, Bairey O, Lavi N, Horowitz N, Avigdor A, Lebel E, Sofer O, Ram R, Avivi I.

Am J Hematol. 2019 Jun 18. doi: 10.1002/ajh.25558. [Epub ahead of print]

PMID:
31211434
14.

A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.

Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ Jr.

Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7. doi: 10.1016/j.ajog.2019.05.006. Epub 2019 May 10.

PMID:
31082382
15.

The impact of communication style on patient satisfaction.

Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L.

Breast Cancer Res Treat. 2019 Jul;176(2):349-356. doi: 10.1007/s10549-019-05232-w. Epub 2019 Apr 25.

PMID:
31025271
16.

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.

Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S.

Gynecol Oncol. 2019 Jun;153(3):471-478. doi: 10.1016/j.ygyno.2019.03.247. Epub 2019 Mar 29.

PMID:
30935717
17.

Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?

Mora PAR, Sun SY, Velarde GC, Filho JR, Uberti EH, Dos Santos Esteves APV, Elias KM, Horowitz NS, Braga A, Berkowitz RS.

Gynecol Oncol. 2019 May;153(2):277-285. doi: 10.1016/j.ygyno.2019.03.005. Epub 2019 Mar 8.

PMID:
30857648
18.

Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.

Gockley AA, Fiascone S, Hicks Courant K, Pepin K, Del Carmen M, Clark RM, Goldberg J, Horowitz N, Berkowitz R, Worley M Jr.

Int J Gynecol Cancer. 2019 Mar;29(3):585-592. doi: 10.1136/ijgc-2018-000154.

PMID:
30833444
19.

Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation.

Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S.

Pract Radiat Oncol. 2019 May;9(3):e257-e265. doi: 10.1016/j.prro.2019.01.013. Epub 2019 Feb 20.

PMID:
30796975
20.

A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma.

Alimena S, Fiascone S, Krasner C, King M, Horowitz N.

Curr Probl Cancer. 2019 Oct;43(5):443-449. doi: 10.1016/j.currproblcancer.2019.01.006. Epub 2019 Feb 7.

PMID:
30770127

Supplemental Content

Loading ...
Support Center